vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and LendingClub Corp (LC). Click either name above to swap in a different company.

BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($406.6M vs $252.3M, roughly 1.6× LendingClub Corp). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 20.5%, a 40.0% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs 15.9%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs 16.1%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

LendingClub Corporation is an American financial services company headquartered in San Francisco, California. It was the first peer-to-peer lender to register its offerings as securities with the Securities and Exchange Commission (SEC), and to offer loan trading on a secondary market. At its height, LendingClub was the world's largest peer-to-peer lending platform. The company reported that $15.98 billion in loans had been originated through its platform up to December 31, 2015.

BCRX vs LC — Head-to-Head

Bigger by revenue
BCRX
BCRX
1.6× larger
BCRX
$406.6M
$252.3M
LC
Growing faster (revenue YoY)
BCRX
BCRX
+193.2% gap
BCRX
209.1%
15.9%
LC
Higher net margin
BCRX
BCRX
40.0% more per $
BCRX
60.5%
20.5%
LC
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
16.1%
LC

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BCRX
BCRX
LC
LC
Revenue
$406.6M
$252.3M
Net Profit
$245.8M
$51.6M
Gross Margin
97.7%
Operating Margin
64.0%
Net Margin
60.5%
20.5%
Revenue YoY
209.1%
15.9%
Net Profit YoY
1017.5%
341.0%
EPS (diluted)
$1.13
$0.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
LC
LC
Q1 26
$252.3M
Q4 25
$406.6M
$266.5M
Q3 25
$159.4M
$266.2M
Q2 25
$163.4M
$248.4M
Q1 25
$145.5M
$217.7M
Q4 24
$131.5M
$217.2M
Q3 24
$117.1M
$201.9M
Q2 24
$109.3M
$187.2M
Net Profit
BCRX
BCRX
LC
LC
Q1 26
$51.6M
Q4 25
$245.8M
Q3 25
$12.9M
$44.3M
Q2 25
$5.1M
$38.2M
Q1 25
$32.0K
$11.7M
Q4 24
$-26.8M
Q3 24
$-14.0M
$14.5M
Q2 24
$-12.7M
$14.9M
Gross Margin
BCRX
BCRX
LC
LC
Q1 26
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Operating Margin
BCRX
BCRX
LC
LC
Q1 26
Q4 25
64.0%
18.8%
Q3 25
18.6%
21.5%
Q2 25
18.2%
21.7%
Q1 25
14.6%
7.2%
Q4 24
-3.4%
5.1%
Q3 24
6.6%
8.9%
Q2 24
8.0%
10.4%
Net Margin
BCRX
BCRX
LC
LC
Q1 26
20.5%
Q4 25
60.5%
Q3 25
8.1%
16.6%
Q2 25
3.1%
15.4%
Q1 25
0.0%
5.4%
Q4 24
-20.4%
Q3 24
-12.0%
7.2%
Q2 24
-11.6%
8.0%
EPS (diluted)
BCRX
BCRX
LC
LC
Q1 26
$0.44
Q4 25
$1.13
$0.36
Q3 25
$0.06
$0.37
Q2 25
$0.02
$0.33
Q1 25
$0.00
$0.10
Q4 24
$-0.13
$0.08
Q3 24
$-0.07
$0.13
Q2 24
$-0.06
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
LC
LC
Cash + ST InvestmentsLiquidity on hand
$274.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$-119.2M
$1.5B
Total Assets
$514.2M
$11.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
LC
LC
Q1 26
Q4 25
$274.7M
Q3 25
$212.9M
Q2 25
$260.0M
Q1 25
$295.1M
Q4 24
$320.9M
Q3 24
$96.8M
Q2 24
$78.4M
Total Debt
BCRX
BCRX
LC
LC
Q1 26
Q4 25
$0
Q3 25
$0
Q2 25
$0
Q1 25
$0
Q4 24
$0
Q3 24
Q2 24
Stockholders' Equity
BCRX
BCRX
LC
LC
Q1 26
$1.5B
Q4 25
$-119.2M
$1.5B
Q3 25
$-387.9M
$1.5B
Q2 25
$-421.6M
$1.4B
Q1 25
$-451.9M
$1.4B
Q4 24
$-475.9M
$1.3B
Q3 24
$-468.6M
$1.3B
Q2 24
$-475.6M
$1.3B
Total Assets
BCRX
BCRX
LC
LC
Q1 26
$11.9B
Q4 25
$514.2M
$11.6B
Q3 25
$446.4M
$11.1B
Q2 25
$457.2M
$10.8B
Q1 25
$480.0M
$10.5B
Q4 24
$490.4M
$10.6B
Q3 24
$491.3M
$11.0B
Q2 24
$472.4M
$9.6B
Debt / Equity
BCRX
BCRX
LC
LC
Q1 26
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
LC
LC
Operating Cash FlowLast quarter
$292.0M
Free Cash FlowOCF − Capex
$291.2M
FCF MarginFCF / Revenue
71.6%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
1.19×
TTM Free Cash FlowTrailing 4 quarters
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
LC
LC
Q1 26
Q4 25
$292.0M
$-2.7B
Q3 25
$41.6M
$-770.8M
Q2 25
$41.3M
$-713.1M
Q1 25
$-27.5M
$-339.3M
Q4 24
$-5.2M
$-2.6B
Q3 24
$8.2M
$-669.8M
Q2 24
$-1.4M
$-932.5M
Free Cash Flow
BCRX
BCRX
LC
LC
Q1 26
Q4 25
$291.2M
$-2.9B
Q3 25
$40.3M
$-791.8M
Q2 25
$41.1M
$-803.8M
Q1 25
$-27.7M
$-352.3M
Q4 24
$-5.9M
$-2.7B
Q3 24
$8.2M
$-682.3M
Q2 24
$-1.5M
$-945.3M
FCF Margin
BCRX
BCRX
LC
LC
Q1 26
Q4 25
71.6%
-1076.0%
Q3 25
25.3%
-297.4%
Q2 25
25.2%
-323.5%
Q1 25
-19.0%
-161.8%
Q4 24
-4.5%
-1237.8%
Q3 24
7.0%
-338.0%
Q2 24
-1.4%
-504.9%
Capex Intensity
BCRX
BCRX
LC
LC
Q1 26
Q4 25
0.2%
52.7%
Q3 25
0.8%
7.9%
Q2 25
0.1%
36.5%
Q1 25
0.1%
6.0%
Q4 24
0.5%
25.0%
Q3 24
0.1%
6.2%
Q2 24
0.1%
6.9%
Cash Conversion
BCRX
BCRX
LC
LC
Q1 26
Q4 25
1.19×
Q3 25
3.23×
-17.41×
Q2 25
8.12×
-18.68×
Q1 25
-859.91×
-29.07×
Q4 24
Q3 24
-46.33×
Q2 24
-62.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons